Trial Profile
A Phase II, Open, Single-arm, Multi-cohort, Multicenter Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Lung cancer; Malignant thymoma; Malignant-mesothelioma; Non-small cell lung cancer; Oropharyngeal cancer; Small cell lung cancer; Squamous cell cancer; Thyroid cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 13 Sep 2022 Results (data cutoff date was on Apr 19, 2022, n=12) evaluating the efficacy and safety of anlotinib in combination with penpulimab in patients with pleural mesothelioma or thymic carcinoma who have received at least one line of chemotherapy, presented at the 47th European Society for Medical Oncology Congress
- 07 Jun 2022 Results from the cohort 1 part of the study for patients with recurrent or metastatic head and neck squamous cell carcinoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology